To investigate how variability in multiple pharmacokinetic genes associates with telmisartan
exposure, we determined telmisartan single‐dose (40 mg) pharmacokinetics and …

Objectives In this study, we evaluated (a) the contribution of SLCO1B3 and UGT1A
polymorphisms to the pharmacokinetics of telmisartan in two forms, a microdose (MD) and a …

Abstract Background and Objective Telmisartan is an angiotensin receptor blocker used for
the treatment of hypertension. The effects of gender and uridine diphosphate …

Objective Telmisartan is mainly taken up into the liver by organic anion transporting
polypeptide (OATP) 1B3, conjugated with glucuronate, and excreted into the bile. We …

Purpose: This study aimed to understand the effects of single nucleotide polymorphisms
(SNPs) in UGT1A1, SLCO1B3, ABCB1, ABCC2, ABCG2, and ORM1 on the …

Background The pharmacokinetics (PKs) and pharmacodynamics (PDs) of telmisartan
varies among the individuals, and the main causes remain unknown. The aim of this study …

Background: Considerable interindividual differences in both drug response and
pharmacokinetics of telmisartan have been identified. This study was designed to …

BACKGROUND: Telmisartan is taken up into human hepatocytes by organic anion-
transporting polypeptide (OATP/gene SLCO) and is glucuronized by uridine diphosphate …

Importance of the field: Telmisartan belongs to the angiotensin II type 1 (AT1) receptor
antagonizing class of antihypertensives, which are widely recognized and increasingly …

Hypertension is one of the major risk factors for cardiovascular disease. Angiotensin
receptor blockers (ARBs) are a class of antihypertensive drugs with established efficacy and …